Literature DB >> 25515790

Renalase is removed by kidneys and during dialysis - excess related to CKD complications?

Jolanta Malyszko1, Ewa Koc-Zorawska, Marcin Zorawski, Piotr Kozminski, Edyta Zbroch, Jacek Rysz, Maciej Banach, Jacek S Malyszko.   

Abstract

BACKGROUND: The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory data about serum renalase because of low activity and high levels revealed in hypertensive patients with CKD. We assessed serum renalase concentration in objects with CKD after one-side and both-side nephrectomy (on haemodialysis [HD]), or hemodiafiltration (HDF), in urine and ultrafiltrate in hemodialysis objects. We also evaluated the influence of hemodialysis sessions on renalase concentrations.
METHODS: The concentration of renalase in plasma, ultrafiltrate and urine of 100 hemodialysis patients was assessed by commercially accessible test. We evaluated renalase in 17 HDF objects and 24 healthy controls. Western Blot test was also used to assess renalase concentration.
RESULTS: Ultrafiltrate in hemodialysis objects contained renalase and there was no impact of dialysers' type (high-flux and low-flux). Renalase concentration of urine in control group was higher than in hemodialysis objects (n=60). The anuric group had higher renalase concentration comparing to those with remaining diuresis (p<0.001). Univariate analysis revealed the correlation between renalase concentration in plasma and in urine (r=-0.28, p<0.05) and ultrafiltrate renalase in hemodialysis group and between renalase in urine in the control group (r=0.61, p<0.01). There was a correlation between urinary renalase and residual diuresis, hemodialysis sessions non-significantly lowered renalase, the type of heparin had no effect on serum renalase levels. HDF patients had significantly lower renalase than HD patients. In Western blot analysis we found that patients after bilateral nephrectomy had the highest renalase, followed by unilateral nephrectomy.
CONCLUSION: Kidneys eliminate renalase and it is possible that the increased renalase has the impact on cardiovascular diseases in chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25515790     DOI: 10.2174/1570161113666141217141805

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  5 in total

1.  Renalase contributes to protection against renal fibrosis via inhibiting oxidative stress in rats.

Authors:  Yiru Wu; Liyan Wang; Xiaoqi Wang; Yahui Wang; Qidong Zhang; Wenhu Liu
Journal:  Int Urol Nephrol       Date:  2018-02-23       Impact factor: 2.370

2.  Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients.

Authors:  Marcin Dziedzic; Tomasz Powrózek; Ewelina Orłowska; Wojciech Koch; Wirginia Kukula-Koch; Kinga Gaweł; Anna Bednarek-Skublewska; Teresa Małecka-Massalska; Janusz Milanowski; Beata Petkowicz; Janusz Solski
Journal:  PLoS One       Date:  2017-06-14       Impact factor: 3.240

3.  Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.

Authors:  Jolanta Malyszko; Ewa Koc-Zorawska; Piotr Kozminski; Jacek S Malyszko
Journal:  Int Urol Nephrol       Date:  2017-01-02       Impact factor: 2.370

4.  Renalase in Haemodialysis Patients with Chronic Kidney Disease.

Authors:  Magda Wisniewska; Natalia Serwin; Violetta Dziedziejko; Małgorzata Marchelek-Mysliwiec; Barbara Dołegowska; Leszek Domanski; Kazimierz Ciechanowski; Krzysztof Safranow; Andrzej Pawlik
Journal:  J Clin Med       Date:  2021-02-10       Impact factor: 4.241

5.  The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients.

Authors:  Magda Wiśniewska; Natalia Serwin; Violetta Dziedziejko; Małgorzata Marchelek-Myśliwiec; Barbara Dołęgowska; Leszek Domański; Kazimierz Ciechanowski; Krzysztof Safranow; Tomasz Gołębiowski; Andrzej Pawlik
Journal:  Int J Environ Res Public Health       Date:  2021-06-10       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.